JP2004285076A5 - - Google Patents

Download PDF

Info

Publication number
JP2004285076A5
JP2004285076A5 JP2004155357A JP2004155357A JP2004285076A5 JP 2004285076 A5 JP2004285076 A5 JP 2004285076A5 JP 2004155357 A JP2004155357 A JP 2004155357A JP 2004155357 A JP2004155357 A JP 2004155357A JP 2004285076 A5 JP2004285076 A5 JP 2004285076A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004155357A
Other languages
Japanese (ja)
Other versions
JP2004285076A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2004285076A publication Critical patent/JP2004285076A/ja
Publication of JP2004285076A5 publication Critical patent/JP2004285076A5/ja
Withdrawn legal-status Critical Current

Links

JP2004155357A 1992-06-09 2004-05-25 M−csfの結晶化 Withdrawn JP2004285076A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP6501713A Division JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化

Publications (2)

Publication Number Publication Date
JP2004285076A JP2004285076A (ja) 2004-10-14
JP2004285076A5 true JP2004285076A5 (OSRAM) 2005-08-11

Family

ID=25406334

Family Applications (2)

Application Number Title Priority Date Filing Date
JP6501713A Withdrawn JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化
JP2004155357A Withdrawn JP2004285076A (ja) 1992-06-09 2004-05-25 M−csfの結晶化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP6501713A Withdrawn JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化

Country Status (7)

Country Link
US (2) US5866114A (OSRAM)
EP (2) EP0668914B1 (OSRAM)
JP (2) JPH08507916A (OSRAM)
AT (1) ATE195553T1 (OSRAM)
CA (1) CA2137793C (OSRAM)
DE (1) DE69329247T2 (OSRAM)
WO (1) WO1993025687A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1997033613A1 (en) * 1996-03-14 1997-09-18 Board Of Trustees Of The University Of Illinois Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
DK1772464T3 (da) 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
BR0211071A (pt) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
EP1706137A2 (en) * 2004-01-21 2006-10-04 Chiron Corporation M-csf muteins and uses thereof
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン, インコーポレイテッド Peg化されたg−csfポリペプチドおよびその製造方法
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
HUE044179T2 (hu) 2009-12-10 2019-10-28 Hoffmann La Roche Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1212214A1 (en) 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
BR112016029460A2 (pt) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc métodos para tratar artrite reumatoide
EA036261B1 (ru) 2014-10-29 2020-10-20 Файв Прайм Терапьютикс, Инк. Комбинированное лечение злокачественного новообразования
EP3237447B1 (en) 2014-12-22 2020-12-02 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
PT3283527T (pt) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Terapêutica de combinação para o cancro
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
JP2020535119A (ja) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗csf1rおよび抗pd−1抗体組合せ併用療法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
DE68918331T2 (de) * 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP0506866B1 (en) * 1989-12-21 1993-10-20 Novo Nordisk A/S Method for crystallization of enzymes
DE69231467T2 (de) * 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden

Similar Documents

Publication Publication Date Title
BE2024C508I2 (OSRAM)
BE2023C542I2 (OSRAM)
BE2022C549I2 (OSRAM)
BE2021C001I2 (OSRAM)
BE2019C506I2 (OSRAM)
BE2018C045I2 (OSRAM)
BE2017C063I2 (OSRAM)
BE2017C027I2 (OSRAM)
BE2016C014I2 (OSRAM)
BE2016C020I2 (OSRAM)
BE2015C041I2 (OSRAM)
BE2015C038I2 (OSRAM)
BE2015C014I2 (OSRAM)
BE2014C071I2 (OSRAM)
BE2015C015I2 (OSRAM)
BE2014C064I2 (OSRAM)
BE2014C063I2 (OSRAM)
BE2014C010I2 (OSRAM)
BE2013C071I2 (OSRAM)
BE2013C021I2 (OSRAM)
BE2015C066I2 (OSRAM)
BE2012C025I2 (OSRAM)
JP2005292347A5 (OSRAM)
BE2015C033I2 (OSRAM)
BE2015C065I2 (OSRAM)